The APOE ε4 variant and hippocampal atrophy in Alzheimer’s disease and Lewy body dementia: a systematic review of magnetic resonance imaging studies and therapeutic relevance

References

• Alzheimer’s Disease International. Dementia statistics. Available online at: https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/ (accessed 2021 Mar 27)
   Google Scholar
• McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–269.
   Google Scholar
• McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology. 2017;89(1):88–100.
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Association. Alzheimer’s disease facts and figures 2020. Alzheimers Dement. 2020;16(3):391–460. Available from: https://alz-journals.onlinelibrary.wiley.com/doi/abs/10.1002/alz.12068.
   Google Scholar
• Braak H, Braak E. Neuropathological Staging of Alzheimer-Related changes. Acta Neuropathol. 1991;82(4):239–259.
   PubMed Web of Science ®Google Scholar
• Jack CR, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer’s Dementia. 2018;14(4):535–562.
   Web of Science ®Google Scholar
• Saeed U, Lang AE, Masellis M. Neuroimaging advances in parkinson’s disease and atypical parkinsonian syndromes. Front Neurol. 2020;11:1189. Available from https://www.frontiersin.org/article/10.3389/fneur.2020.572976.
   Web of Science ®Google Scholar
• Saeed U, Compagnone J, Aviv RI, et al. Imaging biomarkers in Parkinson’s disease and Parkinsonian syndromes: current and emerging concepts. Transl Neurodegener. 2017;6(1):8. Available from: http://dx.doi.org/10.1186/s40035-017-0076-6
   PubMedGoogle Scholar
• Schneider JA, Arvanitakis Z, Bang W, et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197–2204.
   PubMed Web of Science ®Google Scholar
• Schneider JA, Arvanitakis Z, Yu L, et al. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain. 2012;135(10):3005–3014.
   PubMedGoogle Scholar
• Kantarci K, Ferman TJ, Boeve BF, et al. Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology. 2012;79(6):553–560.
   PubMed Web of Science ®Google Scholar
• Duvernoy HM, Cattin F, Risold PY. The human hippocampus: functional anatomy, vascularization and serial sections with MRI, fourth edition. Publisher: Springer-Verlag Berlin Heidelberg; 2013.
   Google Scholar
• Saunders A, Strittmatter W, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer’s disease. Neurology. 1993;43(8):1467–1472.
   PubMed Web of Science ®Google Scholar
• Corder E, Saunders A, Strittmatter W, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer’s disease in late onset families. Science. 1993;261(5123):921–923.
   PubMed Web of Science ®Google Scholar
• Tsuang D, Leverenz JB, Lopez OL, et al. APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol. 2013;70(2):223–228.
   PubMed Web of Science ®Google Scholar
• Liu CC, Kanekiyo T, Xu H, et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106–118.
   PubMed Web of Science ®Google Scholar
• Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc Natl Acad Sci U S A. 2006;103(15):5644–5651.
   PubMed Web of Science ®Google Scholar
• Zhao N, Attrebi ON, Ren Y, et al. APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid. Sci Transl Med. 2020;12(529):eaay1809.
   Web of Science ®Google Scholar
• Hashimoto M, Yasuda M, Tanimukai S, et al. Apolipoprotein E epsilon 4 and the pattern of regional brain atrophy in Alzheimer’s disease. Neurology. 2001;57(8):1461–1466.
   PubMed Web of Science ®Google Scholar
• Wolk DA, Dickerson BC, Weiner M. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2010;107(22):10256–10261.
   PubMed Web of Science ®Google Scholar
• Manning EN, Barnes J, Cash DM, et al. APOE ε4 is associated with disproportionate progressive hippocampal atrophy in AD. PLoS ONE. 2014;9(5):e97608.
   Web of Science ®Google Scholar
• Schuff N, Woerner N, Boreta L, et al. MRI of hippocampal volume loss in early Alzheimer’s disease in relation to ApoE genotype and biomarkers. Brain. 2009;132(4):1067–1077.
   PubMedGoogle Scholar
• Basso M, Gelernter J, Yang J, et al. Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer’s disease. Neurobiol Aging. 2006;27(10):1416–1424.
   PubMed Web of Science ®Google Scholar
• Jack CR, Petersen RC, Xu YC, et al. Hippocampal atrophy and apolipoprotein E genotype are independently associated with Alzheimer’s disease. Ann Neurol. 1998;43(3):303–310.
   PubMed Web of Science ®Google Scholar
• Chiang GC, Insel PS, Tosun D, et al. Impact of apolipoprotein E4-cerebrospinal fluid β-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimer’s & Dementia. 2011;7(5):514–520.
   PubMedGoogle Scholar
• Barnes J, Scahill RI, Schott JM, et al. Does Alzheimer’s disease affect hippocampal asymmetry? Evidence from a cross-sectional and longitudinal volumetric MRI study. Dement Geriatr Cogn Disord. 2005;19(5–6):338–344.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339(1):b2700–b2700.
   PubMed Web of Science ®Google Scholar
• Lehtovirta M, Soininen H, Laakso MP, et al. SPECT and MRI analysis in Alzheimer’s disease: relation to apolipoprotein E epsilon 4 allele. J Neurol Neurosurg Psychiatry. 1996;60(6):644–649.
   PubMed Web of Science ®Google Scholar
• Lehtovirta M, Laakso MP, Soininen H, et al. Volumes of hippocampus, amygdala and frontal lobe in Alzheimer patients with different apolipoprotein E genotypes. Neuroscience. 1995;67(1):65–72.
   PubMed Web of Science ®Google Scholar
• Khan W, Giampietro V, Banaschewski T. A multi-cohort study of ApoE ɛ4 and Amyloid-β Effects on the Hippocampus in Alzheimer’s disease. J Alzheimers Dis. 2017;56(3):1159–1174.
   Google Scholar
• Liu Y, Paajanen T, Westman E, et al. Effect of APOE ε4 allele on cortical thicknesses and volumes: the addNeuroMed study. J Alzheimers Dis. 2010;21(3):947–966.
   PubMed Web of Science ®Google Scholar
• Rosen HJ, Gorno-Tempini ML, Goldman WP, et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology. 2002;58(2):198–208.
   PubMed Web of Science ®Google Scholar
• Agosta F, Vossel KA, Miller BL, et al. Apolipoprotein E epsilon4 is associated with disease-specific effects on brain atrophy in Alzheimer’s disease and frontotemporal dementia. Proc Natl Acad Sci U S A. 2009;106(6):2018–2022.
   PubMed Web of Science ®Google Scholar
• O’Dwyer L, Lamberton F, Matura S, et al. Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI study. PLoS ONE. 2012;7. Available from http://www.plosone.org/article/fetchObjectAttachment.action?uri=info%3Adoi%2F10.1371%2Fjournal.pone.0048895&representation=PDF
   Web of Science ®Google Scholar
• Dean DC, Jerskey BA, Chen K, et al. Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol. 2014;71(1):11–22.
   PubMed Web of Science ®Google Scholar
• Saeed U, Mirza SS, MacIntosh BJ, et al. APOE-ε4 associates with hippocampal volume, learning, and memory across the spectrum of Alzheimer’s disease and dementia with Lewy bodies. Alzheimer’s Dementia. 2018;14(9):1137–1147.
   PubMed Web of Science ®Google Scholar
• Dickson DW, Heckman MG, Murray ME, et al. APOE ε4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology. 2018;91(12):e1182–e1195.
   PubMed Web of Science ®Google Scholar
• Nicoletti G, Manners DN, Novellino F, et al. Voxel-based morphometry to detect effect of APOE on brain gray matter changes in Parkinson’s disease. Psychiatry Res Neuroimaging. 2016;254:177–179.
   PubMed Web of Science ®Google Scholar
• Barber R, Ballard C, McKeith IG, et al. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology. 2000;54(6):1304–1309.
   PubMed Web of Science ®Google Scholar
• Spampinato MV, Rumboldt Z, Hosker RJ, et al. Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease. Radiology. 2011;258(3):843–852.
   PubMed Web of Science ®Google Scholar
• Risacher SL, Shen L, West JD, et al. Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging. 2010;31(8):1401–1418.
   PubMed Web of Science ®Google Scholar
• Nobis L, Manohar SG, Smith SM, et al. Hippocampal volume across age: nomograms derived from over 19,700 people in UK Biobank. NeuroImage Clin. 2019;23:101904.
   PubMed Web of Science ®Google Scholar
• Jack CRJ, Petersen RC, Xu Y, et al. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology. 2000;55(4):484–489.
   PubMed Web of Science ®Google Scholar
• Tang X, Holland D, Am D, et al. APOE affects the volume and shape of the amygdala and the hippocampus in mild cognitive impairment and Alzheimer’s Disease: age matters. Journal of Alzheimer’s Disease. 2015;47(3):645–660.
   PubMed Web of Science ®Google Scholar
• Raz N, Lindenberger U, Rodrigue KM, et al. Regional Brain Changes in Aging Healthy Adults: general Trends, Individual Differences and Modifiers. Available from: https://academic.oup.com/cercor/article/15/11/1676/296890.
   Google Scholar
• Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755–766.
   PubMed Web of Science ®Google Scholar
• Bigler ED, Lowry CM, Anderson CV, et al. Dementia, quantitative neuroimaging, and apolipoprotein E genotype. Am J Neuroradiol. 2000;21:1857–1868.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Galve L, Lehmann M, Hobbs NZ, et al. Patterns of cortical thickness according to APOE genotype in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2009;28(5):476–485.
   PubMed Web of Science ®Google Scholar
• Laakso MP, Lehtovirta M, Partanen K, et al. Hippocampus in Alzheimer’s disease: a 3-year follow-up MRI study. Biol Psychiatry. 1999;47(6):557–561.
   Web of Science ®Google Scholar
• Jack CR, Petersen RC, Xu Y, et al. Rate of medial temporal lobe atrophy in typical aging and Alzheimer’s disease. Neurology. 1998;51(4):993–999.
   PubMed Web of Science ®Google Scholar
• Robinson JL, Lee EB, Xie SX, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141(7):2181–2193.
   PubMedGoogle Scholar
• Kerchner GA, Berdnik D, Shen JC, et al. APOE e4 worsens hippocampal CA1 apical neuropil atrophy and episodic memory. Neurology. 2014;82(8):691–697.
   PubMed Web of Science ®Google Scholar
• Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.
   PubMed Web of Science ®Google Scholar
• Saeed U, Lang AE, Masellis M. Neuroimaging Advances in Parkinson’s Disease and Atypical Parkinsonian Syndromes. Front Neurol. 2020;11:572976.
   PubMed Web of Science ®Google Scholar
• Fujishima M, Kawaguchi A, Maikusa N, et al. Sample size estimation for Alzheimer’s disease trials from Japanese ADNI serial magnetic resonance imaging. JAD. 2017;56(1):75–88.
   PubMedGoogle Scholar
• Filippini N, MacIntosh BJ, Hough MG, et al. Distinct patterns of brain activity in young carriers of the APOE-ε4 allele. Proc Nat Acad Sci. 2009;106(17):7209–7214.
   PubMed Web of Science ®Google Scholar
• Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer’s disease. N Engl J Med. 2000;343(7):450–456.
   PubMed Web of Science ®Google Scholar
• Berlyand Y, Weintraub D, Xie SX, et al. An Alzheimer’s disease-derived biomarker signature identifies parkinson’s disease patients with dementia. PLoS One. 2016;11(1):e0147319.
   PubMed Web of Science ®Google Scholar
• Lo RY, Hubbard AE, Shaw LM, et al. Longitudinal change of biomarkers in cognitive decline. Arch Neurol. 2011;68(10):1257–1266.
   PubMedGoogle Scholar
• Kang JH, Mollenhauer B, Coffey CS, et al. CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s progression markers initiative study. Acta Neuropathol. 2016;131(6):935–949.
   PubMed Web of Science ®Google Scholar
• Lindqvist D, Prokopenko I, Londos E, et al. Associations between TOMM40 Poly-T repeat variants and dementia in cases with Parkinsonism. J Parkinsons Dis. 2016;6(1):99–108.
   PubMedGoogle Scholar
• Hansen TI, Brezova V, Eikenes L, et al. How does the accuracy of intracranial volume measurements affect normalized brain volumes? sample size estimates based on 966 subjects from the HUNT MRI cohort. Am J Neuroradiol. 2015;36(8):1450–1456.
   Web of Science ®Google Scholar
• Ramirez J, Gibson E, Quddus A, et al. Lesion explorer: a comprehensive segmentation and parcellation package to obtain regional volumetrics for subcortical hyperintensities and intracranial tissue. NeuroImage. 2011;54(2):963–973.
   PubMed Web of Science ®Google Scholar
• Nestor SM, Gibson E, Gao FQ, et al. A direct morphometric comparison of five labeling protocols for multi-atlas driven automatic segmentation of the hippocampus in Alzheimer’s disease. NeuroImage. 2013;66:50–70.
   PubMed Web of Science ®Google Scholar
• Boccardi M, Bocchetta M, Apostolova LG, et al. Delphi definition of the EADC-ADNI Harmonized protocol for hippocampal segmentation on magnetic resonance. Alzheimer’s & dementia. 2015;11(2):126–138.
   PubMed Web of Science ®Google Scholar
• Geroldi C, Pihlajamäki M, Laakso MP, et al. APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology. 1999;53(8):1825–1832.
   PubMed Web of Science ®Google Scholar
• Wang X, Wang J, He Y, et al. Apolipoprotein E epsilon4 modulates cognitive profiles, hippocampal volume, and resting-state functional connectivity in Alzheimer’s disease. J Alzheimers Dis. 2015;45(3):781–795.
   Google Scholar
• Boccardi M, Sabattoli F, Testa C, et al. APOE and modulation of Alzheimer’s and frontotemporal dementia. Neurosci Lett. 2004;356(3):167–170.
   PubMed Web of Science ®Google Scholar
• Teng E, Chow N, Hwang KS, et al. Low plasma ApoE levels are associated with smaller hippocampal size in the alzheimer’s disease neuroimaging initiative cohort. Dement Geriatr Cogn Disord. 2015;39(3–4):154–166.
   PubMed Web of Science ®Google Scholar
• Graff-Radford J, Lesnick TG, Boeve BF, et al. Predicting survival in dementia with Lewy bodies with Hippocampal volumetry. Mov Disord. 2016;31(7):989–994.
   PubMed Web of Science ®Google Scholar
• Mak E, Su L, Williams GB, et al. Differential atrophy of hippocampal subfields: a comparative study of dementia with Lewy bodies and Alzheimer disease. Am J Geriatric Psychiatry. 2016;24(2):136–143.
   PubMed Web of Science ®Google Scholar
• Adamowicz DH, Roy S, Salmon DP, et al. Hippocampal α-Synuclein in dementia with Lewy bodies contributes to memory impairment and is consistent with spread of pathology. J Neurosci. 2017;37(7):1675–1684.
   PubMed Web of Science ®Google Scholar
• Mak E, Gabel S, Su L, et al. Multi-modal MRI investigation of volumetric and microstructural changes in the hippocampus and its subfields in mild cognitive impairment, Alzheimer’s disease, and dementia with Lewy bodies. Int Psychogeriatr. 2017;29(4):545–555.
   PubMed Web of Science ®Google Scholar
• Nadal L, Coupé P, Helmer C, et al. Differential annualized rates of hippocampal subfields atrophy in aging and future Alzheimer’s clinical syndrome. Neurobiol Aging. 2020;90:75–83.
   PubMed Web of Science ®Google Scholar
• Dounavi ME, Mak E, Wells K, et al. Volumetric alterations in the hippocampal subfields of subjects at increased risk of dementia. Neurobiol Aging. 2020;91:36–44.
   PubMed Web of Science ®Google Scholar
• Mueller SG, Weiner MW. Selective effect of Age, Apo e4, and Alzheimer’s disease on hippocampal subfields. Hippocampus. 2009;19(6):558–564.
   PubMed Web of Science ®Google Scholar
• Khan W, Westman E, Jones N, et al. Automated hippocampal subfield measures as predictors of conversion from mild cognitive impairment to Alzheimer’s disease in two independent cohorts. Brain Topogr. 2015;28(5):746–759.
   PubMed Web of Science ®Google Scholar
• Pievani M, Galluzzi S, Thompson PM, et al. APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer’s disease. NeuroImage. Internet]. 2011;55:909–919.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Cho H, Kim YJ, et al. Apolipoprotein E4 affects topographical changes in hippocampal and cortical atrophy in Alzheimer’s disease dementia: a five-year longitudinal study. J Alzheimers Dis. 2015;44(4):1075–1085.
   PubMed Web of Science ®Google Scholar
• Yushkevich PA, Amaral RSC, Augustinack JC, et al. Quantitative comparison of 21 protocols for labeling hippocampal subfields and parahippocampal subregions in in vivo MRI: towards a harmonized segmentation protocol. NeuroImage. 2015;111:526–541.
   PubMed Web of Science ®Google Scholar
• Theysohn JM, Kraff O, Maderwald S, et al. The human hippocampus at 7 T—In vivo MRI. Hippocampus. 2009;19:1–7.
   PubMed Web of Science ®Google Scholar
• Kerchner GA, Hess CP, Hammond-Rosenbluth KE, et al. Hippocampal CA1 apical neuropil atrophy in mild Alzheimer disease visualized with 7-T MRI. Neurology. 2010;75(15):1381–1387.
   PubMed Web of Science ®Google Scholar
• Schwarz CG, Gunter JL, Wiste HJ, et al. A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer’s disease severity. NeuroImage Clin. 2016;11:802–812.
   PubMed Web of Science ®Google Scholar
• McKiernan EF, O’Brien JT. 7T MRI for neurodegenerative dementias in vivo: a systematic review of the literature. J Neurol Neurosurg. 2017;88(7):564–574. jnnp-2016-315022.
   Web of Science ®Google Scholar
• Woolard A, Heckers S. Anatomical and functional correlates of human hippocampal volume asymmetry. Psychiatry Res. 2012;201(1):48–53.
   PubMed Web of Science ®Google Scholar
• Soininen HS, Partanen K, Pitkanen A, et al. Volumetric MRI analysis of the amygdala and the hippocampus in subjects with age-associated memory impairment: correlation to visual and verbal memory. Neurology. 1994;44(9):1660–1668.
   PubMed Web of Science ®Google Scholar
• Pedraza O, Bowers D, Gilmore R. Asymmetry of the hippocampus and amygdala in MRI volumetric measurements of normal adults. J Int Neuropsychol Soc. 2004;10(5):664–678.
   PubMed Web of Science ®Google Scholar
• Geroldi C, Apolipoprotein E genotype and hippocampal asymmetry in Alzheimer’s disease: a volumetric MRI study. J Neurol Neurosurg. Internet]. 2000;68:93–96.
   PubMed Web of Science ®Google Scholar
• Tohgi H, Takahashi S, Kato E, et al. Reduced size of right hippocampus in 39- to 80-year-old normal subjects carrying the apolipoprotein E ε4 allele. Neurosci Lett. 1997;236(1):21–24.
   PubMed Web of Science ®Google Scholar
• Soininen H, Partanen K, Pitkanen A, et al. Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E epsilon 4 allele. Neurology. 1995;45(2):391–392.
   PubMed Web of Science ®Google Scholar
• Mata IF, Leverenz JB, Weintraub D, et al. APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease. JAMA Neurol. 2014;71(11):1405.
   PubMed Web of Science ®Google Scholar
• Mata IF, Johnson CO, Leverenz JB, et al. Large-scale exploratory genetic analysis of cognitive impairment in Parkinson’s disease. Neurobiol Aging. 2017;56:211e1–211 e7.
   Web of Science ®Google Scholar
• Monsell SE, Besser LM, Heller KB, et al. Clinical and pathologic presentation in Parkinson’s disease by apolipoprotein e4 allele status. Parkinsonism Relat Disord. 2014;20(5):503–507.
   PubMed Web of Science ®Google Scholar
• Cosentino S, Scarmeas N, Helzner E, et al. APOE ε4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology. 2008;70:1842–1849.
   PubMed Web of Science ®Google Scholar
• Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. JAMA. 1997;278(16):1349–1356.
   PubMed Web of Science ®Google Scholar
• Berge G, Sando SB, Rongve A, et al. Apolipoprotein E ε2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort. J Neurol Neurosurg Psychiatry. 2014;85(11):1227–1231.
   PubMed Web of Science ®Google Scholar
• Hostage CA, Choudhury KR, Doraiswamy PM, et al. Dissecting the gene dose-effects of the APOE e4 and e2 alleles on hippocampal volumes in aging and Alzheimer’s disease. PLoS ONE. 2013;8(2):e54483.
   Web of Science ®Google Scholar
• Berlau DJ, Corrada MM, Head E, et al. ApoE ε2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology. 2009;72(9):829–834.
   PubMed Web of Science ®Google Scholar
• Biffi A, Sonni A, Anderson CD, et al. Variants at APOE influence risk of deep and lobar intracerebral hemorrhage. Ann Neurol. 2010;68(6):934–943.
   PubMed Web of Science ®Google Scholar
• McCarron MO, Nicoll JA. Apolipoprotein E genotype and cerebral amyloid angiopathy-related hemorrhage. Ann N Y Acad Sci. 2000;903:176–179.
   PubMed Web of Science ®Google Scholar
• Graff-Radford J, Boeve BF, Pedraza O, et al. Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain. 2012;135(8):2470–2477.
   Google Scholar
• Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A. 1995;92(26):12260–12264.
   Web of Science ®Google Scholar
• Waring JF, Tang Q, Robieson WZ, et al. APOE-ε4 carrier status and donepezil response in patients with Alzheimer’s disease. Journal of Alzheimer’s Disease. 2015;47(1):137–148.
   PubMed Web of Science ®Google Scholar
• Bizzarro A, Marra C, Acciarri A, et al. Apolipoprotein E ε4 allele differentiates the clinical response to donepezil in Alzheimer’s disease. Dement Geriatr Cogn Disord. 2005;20(4):254–261.
   PubMed Web of Science ®Google Scholar
• Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23):2379–2388.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Petersen RC, Grundman M, et al. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. Neurobiol Aging. 2008;29(9):1285–1295.
   PubMed Web of Science ®Google Scholar
• Reger MA, Watson GS, Frey WH, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging. 2006;27(3):451–458.
   Web of Science ®Google Scholar
• Claxton A, Baker LD, Hanson A, et al. Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s Disease dementia. J Alzheimers Dis. 2015;44(3):897–906.
   Google Scholar
• Risner ME, Saunders AM, Altman JFB, et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer’s disease. The Pharmacogenomics Journal. 2006;6(4):246–254.
   PubMed Web of Science ®Google Scholar
• Cummings JL, Zhong K, Kinney JW, et al. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease. Alzheimer’s Research and Therapy. 2016;8(1). https://doi.org/10.1186/s13195-016-0173-2.
   Google Scholar
• Williams T, Borchelt DR, Chakrabarty P. Therapeutic approaches targeting Apolipoprotein e function in Alzheimer’s disease. Mol Neurodegener. 2020;15(1):8.
   Web of Science ®Google Scholar
• Li Z, Shue F, Zhao N, et al. APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease. Mol Neurodegener. 2020;15(1):63.
   Web of Science ®Google Scholar
• De Jager PL, Bennett DA. An inflection point in gene discovery efforts for neurodegenerative diseases: from syndromic diagnoses toward endophenotypes and the epigenome. JAMA Neurol. 2013;70(6):719–726.
   PubMed Web of Science ®Google Scholar
• Teipel SJ, Ewers M, Wolf S, et al. Multicentre variability of MRI-based medial temporal lobe volumetry in Alzheimer’s disease. Psychiatry Research: Neuroimaging. 2010;182(3):244–250.
   Google Scholar
• Drzezga A, Grimmer T, Henriksen G, et al. Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology. 2009;72(17):1487–1494.
   PubMed Web of Science ®Google Scholar
• Lupton MK, Strike L, Hansell NK, et al. The effect of increased genetic risk for Alzheimer’s disease on hippocampal and amygdala volume. Neurobiol Aging. 2016;40:68–77.
   PubMed Web of Science ®Google Scholar
• Manning EN, Barnes J, Cash DM, et al. APOE epsilon4 is associated with disproportionate progressive hippocampal atrophy in AD. PLoS ONE. 2014;9(5):e97608.
   Web of Science ®Google Scholar
• Mori E, Lee K, Yasuda M, et al. Accelerated hippocampal atrophy in Alzheimer’s disease with apolipoprotein E epsilon4 allele. Ann Neurol. 2002;51(2):209–214.
   PubMed Web of Science ®Google Scholar
• Barnes J, Scahill RI, Schott JM, et al. Does Alzheimer’s disease affect hippocampal asymmetry? Evidence from a cross-sectional and longitudinal volumetric MRI study. Dement Geriatr Cogn Disord. 2005;19(5–6):338–344.
   PubMed Web of Science ®Google Scholar
• Andrawis JP, Hwang KS, Green AE, et al. Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiol Aging. 2012;33(5):856–866.
   PubMed Web of Science ®Google Scholar
• Abushakra S, Porsteinsson AP, Sabbagh M, et al. APOE ε4/ε4 homozygotes with early Alzheimer’s disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline. 2020; Available from: https://doi.org/10.1002/trc2.12117.
   Google Scholar